Romina A. Tejada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Romina A. Tejada has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Rafael Bolaños-Díaz
Unidad de Análisis y Generación de Evidencias en Salud Pública. Centro Nacional de Salud Pública. Instituto Nacional de Salud. Lima, Perú
4 shared publications- Talía Malagón
McGill University
4 shared publications - Armando Baena
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health , Rockville, MD
3 shared publications César Gutiérrez
Universidad Nacional Mayor de San Marcos, Lima, Peru
3 shared publications- Eduardo Luis Franco
Division of Cancer Epidemiology, McGill University, Montreal, QC H4A 3T2, Canada
3 shared publications - Jorge O. Alarcon
Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Lima 15081, Peru
2 shared publications
Latest Publications
- 1 August 2026
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2026 (73) , 155-163
Cervical cancer screening in vaccinated populations: challenges and implications for low- and middle-income countries
Cervical cancer remains a public health problem, with the highest burden in low- and middle-income countries (LMICs). As vaccinated cohorts reach screening age, most modeling and policy discussions about the relationship between screening and vaccination have focused on high-income countries, early adopters of human papillomavirus (HPV) vaccination with robust, well-established cervical cancer screening programs. Challenges and solutions proposed for these settings are not necessarily applicable to LMICs, which have historically lagged in cancer prevention and operate within more constrained health systems. We analyze HPV vaccination patterns by country-level income and highlight inequities across program rollout and coverage. Using 6 LMICs expected to screen vaccinated cohorts before 2030, we outline financial, health-system, and information-system challenges. We examine how mathematical models may guide screening policies and illustrate, through Costa Rica’s experience, how research can support implementation of cervical cancer elimination interventions. LMICs will need cost-effective risk-stratified screening approaches tailored to local resources as cervical cancer risk declines over coming years. However, because many women more than 30 years old have not been vaccinated and remain at risk of developing cervical cancer, global efforts to ensure good-quality screening are crucial.
- 1 August 2026
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2026 (73) , 155-163
Cervical cancer screening in vaccinated populations: challenges and implications for low- and middle-income countries
Cervical cancer remains a public health problem, with the highest burden in low- and middle-income countries (LMICs). As vaccinated cohorts reach screening age, most modeling and policy discussions about the relationship between screening and vaccination have focused on high-income countries, early adopters of human papillomavirus (HPV) vaccination with robust, well-established cervical cancer screening programs. Challenges and solutions proposed for these settings are not necessarily applicable to LMICs, which have historically lagged in cancer prevention and operate within more constrained health systems. We analyze HPV vaccination patterns by country-level income and highlight inequities across program rollout and coverage. Using 6 LMICs expected to screen vaccinated cohorts before 2030, we outline financial, health-system, and information-system challenges. We examine how mathematical models may guide screening policies and illustrate, through Costa Rica’s experience, how research can support implementation of cervical cancer elimination interventions. LMICs will need cost-effective risk-stratified screening approaches tailored to local resources as cervical cancer risk declines over coming years. However, because many women more than 30 years old have not been vaccinated and remain at risk of developing cervical cancer, global efforts to ensure good-quality screening are crucial.
- Open Access
Quality of life in women with a human papillomavirus-positive screening test, cervical neoplasia, or cervical cancer in Latin America
Purpose: Human papillomavirus (HPV) infection and HPV-associated diseases impact health-related quality of life (HRQOL). We aimed to measure HRQOL in women with HPV-positive test results, cervical intraepithelial neoplasia (CIN), or cervical cancer in Latin America. Methods: We enrolled women aged 18 to 75 years from Bolivia, Colombia, Honduras, Peru, and Uruguay. We used the EQ-5D-5L instrument to calculate EQ-5D index scores with country-specific sets of health preferences when available. We calculated medians and interquartile ranges (IQR) of EQ-5D index and conducted an exploratory analysis comparing HRQOL loss by diagnosis and country with a gamma regression. Results: We present results from 1,073 participants. Median age was 43 years (IQR: 34-52). The EQ-5D index scores by diagnosis were as follows: HPV-positive test alone 0.906 (standard deviation [SD]: 0.129), CIN1: 0.891 (SD: 0.136), CIN2: 0.892 (SE: 0.124), CIN3: 0.870 (SD: 0.138), and cervical cancer: 0.737 (SD: 0.268). HRQOL was associated with age, diagnosis, and country; there was a significant decreasing trend in HRQOL with worsening health state. Women with cervical cancer had a 3.19-fold higher HRQOL loss than women with an HPV-positive test alone or CIN1. We also found significant differences in HRQOL loss across countries, after adjustment for diagnosis and sociodemographic factors. Conclusion: HRQOL decreased with diagnosis severity, with significant differences between countries. To conduct cost-effectiveness modeling on HPV preventive interventions, obtaining accurate HRQOL estimates is essential. This process should consider the diverse local health preferences influenced by sociodemographic and cultural factors, as well as the population’s beliefs and experiences regarding health. PLAIN ENGLISH SUMMARY: Human papillomavirus (HPV) infection can cause precancerous lesions and cervical cancer, but there is limited information about how these conditions affect women’s quality of life, especially in low- and middle-income countries where the disease burden is highest. This study aimed to measure quality of life among women with HPV-positive test results, precancerous cervical lesions, and cervical cancer in Latin America. We included 1,073 women aged 18 to 75 years from Bolivia, Colombia, Honduras, Peru, and Uruguay. Participants completed the EQ-5D-5L, an internationally validated questionnaire used to measure health-related quality of life. We found that quality of life worsened as disease severity progressed. Women with cervical cancer experienced a 3.19-fold greater loss in quality of life compared with women who had an HPV-positive test result or mild precancerous lesions (CIN1). We also found important differences between countries. These findings provide locally relevant quality-of-life estimates that can be used in future economic evaluations to help identify the most efficient strategies for preventing and treating cervical cancer and precancerous lesions in Latin America.
Open AccessQuality of life in women with a human papillomavirus-positive screening test, cervical neoplasia, or cervical cancer in Latin America
Purpose: Human papillomavirus (HPV) infection and HPV-associated diseases impact health-related quality of life (HRQOL). We aimed to measure HRQOL in women with HPV-positive test results, cervical intraepithelial neoplasia (CIN), or cervical cancer in Latin America. Methods: We enrolled women aged 18 to 75 years from Bolivia, Colombia, Honduras, Peru, and Uruguay. We used the EQ-5D-5L instrument to calculate EQ-5D index scores with country-specific sets of health preferences when available. We calculated medians and interquartile ranges (IQR) of EQ-5D index and conducted an exploratory analysis comparing HRQOL loss by diagnosis and country with a gamma regression. Results: We present results from 1,073 participants. Median age was 43 years (IQR: 34-52). The EQ-5D index scores by diagnosis were as follows: HPV-positive test alone 0.906 (standard deviation [SD]: 0.129), CIN1: 0.891 (SD: 0.136), CIN2: 0.892 (SE: 0.124), CIN3: 0.870 (SD: 0.138), and cervical cancer: 0.737 (SD: 0.268). HRQOL was associated with age, diagnosis, and country; there was a significant decreasing trend in HRQOL with worsening health state. Women with cervical cancer had a 3.19-fold higher HRQOL loss than women with an HPV-positive test alone or CIN1. We also found significant differences in HRQOL loss across countries, after adjustment for diagnosis and sociodemographic factors. Conclusion: HRQOL decreased with diagnosis severity, with significant differences between countries. To conduct cost-effectiveness modeling on HPV preventive interventions, obtaining accurate HRQOL estimates is essential. This process should consider the diverse local health preferences influenced by sociodemographic and cultural factors, as well as the population’s beliefs and experiences regarding health. PLAIN ENGLISH SUMMARY: Human papillomavirus (HPV) infection can cause precancerous lesions and cervical cancer, but there is limited information about how these conditions affect women’s quality of life, especially in low- and middle-income countries where the disease burden is highest. This study aimed to measure quality of life among women with HPV-positive test results, precancerous cervical lesions, and cervical cancer in Latin America. We included 1,073 women aged 18 to 75 years from Bolivia, Colombia, Honduras, Peru, and Uruguay. Participants completed the EQ-5D-5L, an internationally validated questionnaire used to measure health-related quality of life. We found that quality of life worsened as disease severity progressed. Women with cervical cancer experienced a 3.19-fold greater loss in quality of life compared with women who had an HPV-positive test result or mild precancerous lesions (CIN1). We also found important differences between countries. These findings provide locally relevant quality-of-life estimates that can be used in future economic evaluations to help identify the most efficient strategies for preventing and treating cervical cancer and precancerous lesions in Latin America.
- Open Access
- 5 May 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 58, 101483
Impact of switching from a quadrivalent to a nonavalent HPV vaccine on HPV infections and cervical cancer in Colombia: a mathematical modelling study
- 5 May 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 58, 101483
Open AccessImpact of switching from a quadrivalent to a nonavalent HPV vaccine on HPV infections and cervical cancer in Colombia: a mathematical modelling study
- Top Cited Papers
- 17 May 2024
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (7) , 522-538
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination
Cervical cancer is the first cancer deemed amenable to elimination through prevention, and thus lessons from the epidemiology and prevention of this cancer type can provide information on strategies to manage other cancers. Infection with the human papillomavirus (HPV) causes virtually all cervical cancers, and an important proportion of oropharyngeal, anal and genital cancers. Whereas 20th century prevention efforts were dominated by cytology-based screening, the present and future of HPV-associated cancer prevention relies mostly on HPV vaccination and molecular screening tests. In this Review, we provide an overview of the epidemiology of HPV-associated cancers, their disease burden, how past and contemporary preventive interventions have shaped their incidence and mortality, and the potential for elimination. We particularly focus on the cofactors that could have the greatest effect on prevention efforts, such as parity and human immunodeficiency virus infection, as well as on social determinants of health. Given that the incidence of and mortality from HPV-associated cancers remain strongly associated with the socioeconomic status of individuals and the human development index of countries, elimination efforts are unlikely to succeed unless prevention efforts focus on health equity, with a commitment to both primary and secondary prevention.
- 17 May 2024
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (7) , 522-538
Top Cited PapersEpidemiology of HPV-associated cancers past, present and future: towards prevention and elimination
Cervical cancer is the first cancer deemed amenable to elimination through prevention, and thus lessons from the epidemiology and prevention of this cancer type can provide information on strategies to manage other cancers. Infection with the human papillomavirus (HPV) causes virtually all cervical cancers, and an important proportion of oropharyngeal, anal and genital cancers. Whereas 20th century prevention efforts were dominated by cytology-based screening, the present and future of HPV-associated cancer prevention relies mostly on HPV vaccination and molecular screening tests. In this Review, we provide an overview of the epidemiology of HPV-associated cancers, their disease burden, how past and contemporary preventive interventions have shaped their incidence and mortality, and the potential for elimination. We particularly focus on the cofactors that could have the greatest effect on prevention efforts, such as parity and human immunodeficiency virus infection, as well as on social determinants of health. Given that the incidence of and mortality from HPV-associated cancers remain strongly associated with the socioeconomic status of individuals and the human development index of countries, elimination efforts are unlikely to succeed unless prevention efforts focus on health equity, with a commitment to both primary and secondary prevention.
- 1 December 2021
- Published by Elsevier in Value in Health Regional Issues
- Vol. 26, 56-65
Comparison of EQ-5D Values Sets Among South American Countries
- 1 December 2021
- Published by Elsevier in Value in Health Regional Issues
- Vol. 26, 56-65
Comparison of EQ-5D Values Sets Among South American Countries
- Open Access
- 25 June 2019
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 36 (2) , 207-213
Sintomáticos respiratorios en personas atendidas en establecimientos de salud del Ministerio de Salud en Lima, Perú
The aim of this study was to determine the percentage of symptomatic respiratory (SR) cases, according to the programmatic definition, among people who attend medical offices at first-level health facilities of the Ministry of Health in Lima under normal circumstances. The study also aims at identifying the percentage of patients with tuberculosis among the RS and among coughers over seven days. Cross-sectional study of patients attending consultations at 57 health centers. Patients with cough and phlegm lasting more than seven days and RS were identified and a sputum sample was taken to rule out tuberculosis by smear and culture. A total of 10,421 people was surveyed. A 2.7% had cough with phlegm for ≥7 days and only 1.1% were SR; 215 patients were screened for tuberculosis. Seven (5.9%) of the RS and eight (4.8%) of the patients with a 7-14-day cough had tuberculosis. The percentage of RS in the Ministry of Health's health facilities in Lima was less than the expected 5%, ranging from 0.8% in Callao to 1.5% in Lima City. The percentage of tuberculosis among coughers (lasting 7-14 days) and RS is consistent with the findings of other local studies. Consideration should be given to lowering the RS target to less than 5% and expanding tuberculosis screening to patients with cough ≥7 days at the Health Divisions with high tuberculosis incidence.
- 25 June 2019
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 36 (2) , 207-213
Open AccessSintomáticos respiratorios en personas atendidas en establecimientos de salud del Ministerio de Salud en Lima, Perú
The aim of this study was to determine the percentage of symptomatic respiratory (SR) cases, according to the programmatic definition, among people who attend medical offices at first-level health facilities of the Ministry of Health in Lima under normal circumstances. The study also aims at identifying the percentage of patients with tuberculosis among the RS and among coughers over seven days. Cross-sectional study of patients attending consultations at 57 health centers. Patients with cough and phlegm lasting more than seven days and RS were identified and a sputum sample was taken to rule out tuberculosis by smear and culture. A total of 10,421 people was surveyed. A 2.7% had cough with phlegm for ≥7 days and only 1.1% were SR; 215 patients were screened for tuberculosis. Seven (5.9%) of the RS and eight (4.8%) of the patients with a 7-14-day cough had tuberculosis. The percentage of RS in the Ministry of Health's health facilities in Lima was less than the expected 5%, ranging from 0.8% in Callao to 1.5% in Lima City. The percentage of tuberculosis among coughers (lasting 7-14 days) and RS is consistent with the findings of other local studies. Consideration should be given to lowering the RS target to less than 5% and expanding tuberculosis screening to patients with cough ≥7 days at the Health Divisions with high tuberculosis incidence.
- 15 March 2019
- Published by Wolters Kluwer Health in AIDS
- Vol. 33 (4) , 764-765
Use of meta-analysis in systematic review
We have read the systematic review of Kamitani et al.[1], published in your journal with great interest. We consider that this study is very useful because it shows the increasing tendency that the use of preexposure prophylaxis (PrEP) has had over time, especially in MSM. However, we think that there are some methodological aspects worthy of comment, such as the combination of results in a meta-analysis when the reported studies’ heterogeneity is high [1]. Firstly, we must emphasize that the level of statistical heterogeneity shown in the analyses carried out on the prevalence of self-reported PrEP at the Globe (I 2 = 97.7%) is higher than that recommended by Cochrane for carrying out a meta-analysis (I 2 < 75%) [2]. Therefore, we consider that it should not have been performed. The authors ought to consider refraining from the meta-analysis and explore the causes of heterogeneity [3]. Although the authors acknowledge that the high heterogeneity is a limitation, we believe that presenting the results may confuse readers who are not trained in systematic reviews, who would consider the 2.6% of the global value presented as correct when it may not be accurate as such. Also, this can happen because the clinical variability among the studies included in the present systematic review is high, taking into account, for example, that the population is diverse. Secondly, the representativeness of the population could have also been affected, as the largest number of reported studies have been performed in MSM (58 studies out of 72). Therefore, the global self-reported PrEP value, calculated through a meta-analysis, actually represents the MSM population to a large extent. Populations at risk of acquiring HIV have different factors and behaviours; likewise, there may be combinations of exposures that increase the risk of HIV acquisition [4]. For example, MSM can also be IDUs or sex workers. Therefore, we consider that it would have been of greater interest to not only present the prevalence values of self-reported PrEP per year, but also to mention these frequencies in subgroups according to the risk population, in addition to MSM. Although, due to the limited number of studies, a meta-analysis could not be carried out in each subgroup, it is advisable to make a qualitative synthesis that could be useful for the implementation and application in clinical practice guidelines for HIV prevention according to risk groups. For example, reviewing the selected articles, we found that the prevalence of self-reported PrEP in IDU women is 0.8% and in female sex workers is 1.4% in comparison with the overall value presented of 2.6%. In addition, we consider that the authors should use the guide ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)’ to avoid omitting important data at the time of reporting and also ensuring the quality of this. In conclusion, it is important to emphasize that a systematic review in itself already provides valuable and reliable information, due to its careful methodology, to be applied in many tools within evidence-based medicine. In this sense, meta-analysis is a statistical test that must comply with certain assumptions, and its inappropriate use can affect the validity of the systematic review. Therefore, it should always be considered as a tool to enrich the information obtained and never the goal of it [2]. There are no conflicts of interest.
- 15 March 2019
- Published by Wolters Kluwer Health in AIDS
- Vol. 33 (4) , 764-765
Use of meta-analysis in systematic review
We have read the systematic review of Kamitani et al.[1], published in your journal with great interest. We consider that this study is very useful because it shows the increasing tendency that the use of preexposure prophylaxis (PrEP) has had over time, especially in MSM. However, we think that there are some methodological aspects worthy of comment, such as the combination of results in a meta-analysis when the reported studies’ heterogeneity is high [1]. Firstly, we must emphasize that the level of statistical heterogeneity shown in the analyses carried out on the prevalence of self-reported PrEP at the Globe (I 2 = 97.7%) is higher than that recommended by Cochrane for carrying out a meta-analysis (I 2 < 75%) [2]. Therefore, we consider that it should not have been performed. The authors ought to consider refraining from the meta-analysis and explore the causes of heterogeneity [3]. Although the authors acknowledge that the high heterogeneity is a limitation, we believe that presenting the results may confuse readers who are not trained in systematic reviews, who would consider the 2.6% of the global value presented as correct when it may not be accurate as such. Also, this can happen because the clinical variability among the studies included in the present systematic review is high, taking into account, for example, that the population is diverse. Secondly, the representativeness of the population could have also been affected, as the largest number of reported studies have been performed in MSM (58 studies out of 72). Therefore, the global self-reported PrEP value, calculated through a meta-analysis, actually represents the MSM population to a large extent. Populations at risk of acquiring HIV have different factors and behaviours; likewise, there may be combinations of exposures that increase the risk of HIV acquisition [4]. For example, MSM can also be IDUs or sex workers. Therefore, we consider that it would have been of greater interest to not only present the prevalence values of self-reported PrEP per year, but also to mention these frequencies in subgroups according to the risk population, in addition to MSM. Although, due to the limited number of studies, a meta-analysis could not be carried out in each subgroup, it is advisable to make a qualitative synthesis that could be useful for the implementation and application in clinical practice guidelines for HIV prevention according to risk groups. For example, reviewing the selected articles, we found that the prevalence of self-reported PrEP in IDU women is 0.8% and in female sex workers is 1.4% in comparison with the overall value presented of 2.6%. In addition, we consider that the authors should use the guide ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)’ to avoid omitting important data at the time of reporting and also ensuring the quality of this. In conclusion, it is important to emphasize that a systematic review in itself already provides valuable and reliable information, due to its careful methodology, to be applied in many tools within evidence-based medicine. In this sense, meta-analysis is a statistical test that must comply with certain assumptions, and its inappropriate use can affect the validity of the systematic review. Therefore, it should always be considered as a tool to enrich the information obtained and never the goal of it [2]. There are no conflicts of interest.
- Open Access
- 2 May 2018
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 26 (2) , 148-149
Chronic Hepatitis C and Health-Related Quality of Life in Patients with Cognitive Impairment
Qualidade de vida · Hepatite C crônica · Comprometimento cognitive · Cuidadores ·
- 2 May 2018
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 26 (2) , 148-149
Open AccessChronic Hepatitis C and Health-Related Quality of Life in Patients with Cognitive Impairment
Qualidade de vida · Hepatite C crônica · Comprometimento cognitive · Cuidadores ·
- 30 April 2018
- Published by Elsevier in Psychiatry Research
- Vol. 263, 280
A comment on “Body image and paranoia”
- 30 April 2018
- Published by Elsevier in Psychiatry Research
- Vol. 263, 280
A comment on “Body image and paranoia”